{
"info": {
"nct_id": "NCT04541420",
"official_title": "An Observational, Retrospective Study of Eribulin in Advanced Breast Cancer",
"inclusion_criteria": "1. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.\n2. Eribulin treatment of advanced breast cancer for at least one cycle, between Dec 2019 and Aug 2020.\n3. Available medical history.\nHealthy volunteers allowed\nMust be FEMALE",
"exclusion_criteria": "1. Incomplete medical history.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.",
"criterions": [
{
"exact_snippets": "Advanced breast cancer included unresectable locally advanced breast cancer",
"criterion": "unresectable locally advanced breast cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Advanced breast cancer included ... de novo stage IV breast cancer",
"criterion": "de novo stage IV breast cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Advanced breast cancer included ... recurrent metastatic breast cancer",
"criterion": "recurrent metastatic breast cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "2. Eribulin treatment of advanced breast cancer for at least one cycle, between Dec 2019 and Aug 2020.",
"criterions": [
{
"exact_snippets": "Eribulin treatment of advanced breast cancer",
"criterion": "Eribulin treatment",
"requirements": [
{
"requirement_type": "condition",
"expected_value": "advanced breast cancer"
}
]
},
{
"exact_snippets": "at least one cycle",
"criterion": "Eribulin treatment",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "cycle"
}
}
]
},
{
"exact_snippets": "between Dec 2019 and Aug 2020",
"criterion": "Eribulin treatment",
"requirements": [
{
"requirement_type": "time period",
"expected_value": "between Dec 2019 and Aug 2020"
}
]
}
]
},
{
"line": "3. Available medical history.",
"criterions": [
{
"exact_snippets": "Available medical history.",
"criterion": "medical history",
"requirements": [
{
"requirement_type": "availability",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "value",
"expected_value": "female"
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Incomplete medical history.",
"criterions": [
{
"exact_snippets": "Incomplete medical history",
"criterion": "medical history",
"requirements": [
{
"requirement_type": "completeness",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}